Business
Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting
MINNEAPOLIS, March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring
About this update from Bio-techne Corp
[{"type":"text","content":"MINNEAPOLIS, March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place from March 22-27 in Boston, MA. Advanced Cell Diagnostics (ACD), a Bio-Techne brand, will be exhibiting and showcasing RNAscope technology at booth #222.\nLeading pathologists will describe how they have used RNAscope technology to detect clinically relevant biomarkers, including secreted proteins, point mutations and chromosomal translocations, with the potential to improve performance over existing methods and reduce time to results. The session \"RNAscope: Lightning Lunch and Learn\" at noon on Tuesday, March 25, will highlight four pathologists describing their work using RNAscope technology:\nDr. Rohit Mehra, Professor of Pathology at the University of Michigan, will describe TRIM63 mRNA as a surrogate marker in translocation-associated renal cell carcinoma, as an option to traditional DNA FISH.Dr. Vikram Deshpande, Professor of Pathology at Beth Israel Deaconess Medical Center, will detail how albumin mRNA can be a superior marker to secreted protein in primary and secondary liver tumors.Dr. Brooke Howitt, Associate Professor of Pathology at Stanford University, will present advances in the in situ detection of point mutations in molecularly defined gynecologic tumors.Dr. Gregory Bean, Associate Professor of Pathology at Stanford University, will describe the direct detection of mRNA from CRTC1/3::MAML2 translocations, as alternatives to MAML2 FISH, in the identification of mucoepidermoid carcinomas and hidradenomas.\"We've made exciting advancements on in situ hybridization methods enabling novel applications in pathology laboratories,\" commented Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment. \"This conference session highlights the frontier of clinical and translational research by leading pathologists using the latest RNAscope technologies for detecting the molecular underpinnings of disease.\"\nFor Research Use Only. Not intende...